Skip to main content

Development of FKBP51-Inhibitors to treat stress-related disorders: assessment of feasibility

Objective

The FK506-binding protein 51 (FKBP51) plays an important role in the human stress response. In research funded by my ERC Starting Grant I identified the molecular mechanisms of how a de-repressed FKBP51 mediates stress- and trauma-induced risk for psychiatric disorders in genetically vulnerable individuals, thus validating FKBP51 as a potential drug target for stress-related disorders. The current proof-of-concept proposal aims at providing a due diligence analysis to support the concept that the development of FKBP51-directed drugs is technically feasible and economically warranted.

Call for proposal

ERC-2013-PoC
See other projects for this call

Funding Scheme

CSA-SA(POC) - Supporting action (Proof of Concept)

Host institution

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Address
Hofgartenstrasse 8
80539 Munich
Germany
Activity type
Other
EU contribution
€ 150 000
Administrative Contact
Silvia Juckoff

Beneficiaries (1)

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Germany
EU contribution
€ 150 000
Address
Hofgartenstrasse 8
80539 Munich
Activity type
Other
Administrative Contact
Silvia Juckoff